

# **Influence of Gut Resistome on Humans with Autism Spectrum Disorder**

## **ABSTRACT**

Recent studies have shed light on the connection between the gut resistome and .premature birth and exposure to drugs in utero can have a significant impact on children with ASD. Microorganisms present in wastewater, hospitals, and animal production wastewaters have been found to contain various antibiotic-resistant genes (ARGs) that encode resistance to a broad spectrum of antibiotics. Environmental variables are currently considered potential etiological agents of this condition, as genetics alone cannot explain its primary origin. Numerous bacteria found in the gut microbiota (GM) have an impact on human health. Furthermore, a microbe impacted by birth mode, lifestyle, and genetics is present in the intestine. To produce different compounds that affect the host, train the host's immunity, modify drug action and metabolism, regulate gut endocrine function, and eliminate toxins, for example, GM is essential to achieving the intended target for treatment application.

Keywords: gut endocrine function, Autism spectrum disorder, Environmental stresses, Microorganisms

## **INTRODUCTION**

Autism spectrum disorder (ASD) is a major neurodevelopmental issue that affects roughly 1% of the general population. ASD symptoms include repetitive behaviours and trouble with social communication[1].Epidemiological studies indicate that children with ASD often experience emotional and behavioural difficulties, such as anxiety, sadness, hyperactivity, inattention, and aggressive behaviours, in addition to the innate signs of the disorder[1].Environmental stresses such as early birth and drug exposure in utero can have an impact on kids with ASD[2, 3].Furthermore, the pathophysiology of ASD is associated with maternal infection during pregnancy, which raises the likelihood that the child would experience ASD[4].According to the Centers for Disease Control (CDC), one in 54 children in the US has ASD, indicating that the prevalence of ASD is rising globally[5].In certain situations, the diagnosis of ASD can be made as early as 18 months of age. However, a definitive diagnosis might take longer, or in certain situations, it might not be discovered until the patient is a teenager or an adult[6].The aetiology of ASD remains uncertain despite numerous explanations being postulated by environmental and genetic variables[6].According to a wealth of research, alterations in the makeup and function of the gut microbiota (GM) are considered crucial components of ASD[7, 8].According to Kovtun et al. (2020), GM plays a part in communication between the brain and the gut. Additionally, through its interactions with the immune system, the gut microbiome may impact brain function[9].Furthermore, long-term disruption of GM, which is linked to the emergence of gastrointestinal (GI)

symptoms, may result from early-life antibiotic exposure[10-12]. Nonetheless, according to Schulfer et al. (2018), antibiotics are necessary for the treatment of several illnesses, including TB and gonorrhoea, and alterations in the GM composition may be linked to ASD[13].

Thousands of bacterial species comprise the gut microbiome, home to a reservoir of antibiotic resistance genes (ARGs) known as the resistome[20]. In various settings, including the gut, soils, human, animal, and ocean, resistome—a collection of antibiotic resistance genes (ARGs) in a microbial community or on a single microorganism—has been studied[14]. According to Martinez (2014) and Munita and Arias (2016), susceptible bacteria can develop antibiotic resistance by accumulating mutations or acquiring resistance genes through transformation, transduction, and conjugation[15, 16]. These genes provide the cell with resistance to antibiotics. A mutation can be acquired or innate. Furthermore, using antibiotics and bacteria that pose a risk to humans and animals can accelerate the development of antibiotic-resistant genes (ARG). Microorganisms found in wastewaters, hospitals, and animal production wastewaters have been found to harbour hundreds of distinct ARGs that encode resistance to a broad spectrum of antibiotics[17]. To make it easier to characterise and identify ARGs, the Antibiotic Resistance Genes Database (ARDB) is a database that contains the majority of the publicly available data on antibiotic resistance. An extensive amount of information is annotated for each type of resistance and gene, including sequencing, resistance profile, protein databases, ontology, mechanism of action, COG (Clusters of Orthologous Genes), and CDD (Conserved Domain Database) annotations[18]. Examples of ARGs that have been found in the environment include those that are resistant to vancomycin, sulfamethoxazole, trimethoprim, ciprofloxacin, quinolone, or tetracycline (e.g., *sul I*, *sul II*, *tet(A)*, *tet(B)*, *tet(C)*, *tet(G)*, *tet(M)*, *tet(W)*, and *tet(O)*). According to studies, ear infections may raise the chance of ASD, and postnatal antibiotic exposure—particularly the usage of paracetamol and antibiotics—has been linked to ASD[19]. Compared to their contemporaries, children with autism are known to receive an excessive amount of antibiotic treatment[20]. Furthermore, Sharma and colleagues (2016) provided evidence of a connection between ASD and resistome[21].

### **AUTISM SPECTRUM DISORDER (ASD)**

According to Pulikkan, Mazumder, and Grace (2019), autism spectrum disorder (ASD) is regarded as a severe neuropsychiatric and neurodevelopmental illness with an unclear aetiology and pathogenesis[22]. Individual differences may exist in the restrictive, repetitive, communicative, and social issues associated with ASD[23]. ASD is associated with a wide range of comorbidities, such as abnormalities in sensory processing, impaired neural processing, altered brain development, motor deficits, gastrointestinal (GI) disturbances, deficits in verbal and language communication skills, and impairments in intellect and abstract reasoning[24]. Up to 90% of children with ASD have aberrant sensory perception, which is a characteristic of the illness[25]. Furthermore, there is a higher prevalence of GI symptoms in people with ASD, including food intolerance, inflammatory diseases, constipation, flatulence, reflux,

gastrointestinal problems, and indicators of irritable bowel syndrome (IBS)[26].The Centres for Disease Control and Prevention (CDC) stated that roughly one in 44 American children had ASD in 2021, indicating an increase in the frequency of ASD cases. 2.81 incidences of ASD were reported per 1,000 children in Saudi Arabia, with Makkah and Jeddah having the highest prevalence[27].Furthermore, compared to other wealthy nations, the prevalence of ASD is said to be slightly greater[28].Moreover, Hayat et al. (2019) estimate that the prevalence of ASD in the Arab Gulf countries ranges from 1.4 to 29/10,000.[29].Globally, males are more prone to having Autism Spectrum Disorder (ASD) than females. Boys have a 4.5 times greater infection rate than girls[30].ASD manifests in the first three years of life[26].Autism can be diagnosed as early as 18 to 24 months of age; at this time, distinguishable symptoms from other developmental delays can be made. As early as 18 to 24 months of age, autism can be diagnosed, and it is possible to differentiate between the disorder's distinctive symptoms and other developmental abnormalities[31].The diagnosis of ASD can be challenging because its symptoms are similar to those of different psychiatric conditions. Moreover, ASD has a neurodevelopmental basis, and social and non-social symptoms, such as unusually narrow interests, communication and relationship difficulties, and highly repetitive and restrictive behavioural patterns, are used to diagnose the disorder.There is strong evidence that the genetic component of heritability for ASD ranges from 60% to 83%, even when the exact cause of the disorder is unknown[32, 33].Furthermore, a growing body of research indicates that ASD may be brought on by several diseases[34].Environmental variables are currently considered potential etiological agents of this condition, as genetics alone cannot explain its primary origin[35].A growing number of studies employ indirect methods to deduce the aetiology of ASD from epidemiological data[36].Genetics, epigenetics, and environmental variables are only a few of the numerous risk factors for ASD. Though their exact role in ASD is unknown, the microbiota is the most crucial component. It may be able to comprehend the aetiology of ASD through the relationship between ASD and gut resistome[1].All of the genes that confer antibiotic resistance in both pathogenic and non-pathogenic bacteria populations are known as the resistome. Several investigations have elucidated the connection between gut microbiota and ASD. Constipation is a gastrointestinal syndrome that affects 20% of children with ASD, making up a more significant percentage of affected persons than healthy children. By contrast, the ASD person's diarrhoea rate was 19% greater than that of the healthy person. Substantial evidence links GM to ASD through effects on the immune system and metabolism[1, 37].


## **MICROBIOME**

The human gastrointestinal tract (GI) harbours around a thousand distinct microbiome species. The term "human gut microbiome" (GM) refers to the genes and microorganisms found in environmental settings[38]. Numerous bacteria found in GM have an impact on human health. Furthermore, a microbe impacted by birth mode, lifestyle, and genetics is present in the intestine. In order to produce different compounds that affect the host, train the host's immunity, modify drug action and metabolism, regulate gut endocrine function, and eliminate toxins, for example, GM is essential to achieving the intended target for treatment application[39]. According to Sarkar et al. (2010), microbiome alteration results in a critical therapeutic target for sustaining the course of treatment and overall disease wellness. Several investigations have indicated that gut microbiota impacts the immune system, mucosal tissues, and various organs[40]. Variations in the makeup and function of an individual's gut microbiome have been related to inflammatory, metabolic, neurological, cardiovascular, and respiratory disorders[41]. Infection and smoking are the two most significant environmental factors that affect oral/intestinal dysbiosis, arthritic result, and onset[42]. Since germ-free mice do not develop experimental arthritis, the microbiome may be involved in the disease's aetiology. One of the hallmarks of chronic autoimmune inflammatory disease Rheumatoid arthritis (RA) is joint degeneration. Without treatment, RA patients' gut microbiota differed significantly from healthy controls [43]. According to Wells et al. (2020), there appears to be a reduction in the genetic diversity of rheumatoid arthritis patients compared to healthy controls. Furthermore, *Prevotella* species, including *Prevotellacopri*, were more prevalent in the compositional level of bacteria in RA patients[44]. Additionally, *Prevotellacopri* was shown to be more abundant in the colon in recent preclinical phase research on RA patients in European nations, suggesting that dysbiosis occurs before arthritis develops[45]. The aetiology of irritable bowel syndrome (IBS) is linked to dysbiosis in the gut, and there is a decrease in *faecalibacterium* and an increase in *collinsella* in RA[46, 47]. Numerous researchers have demonstrated that gut microbiota dysbiosis may be crucial in neurological and psychiatric illnesses[48].

The gut microbiota of individuals with ASD is different; research found that the number of Prevotellaceae and Porphyromonadaceae was higher in healthy mice compared to autistic mice, as well as an increased number of Erysipelotrichaceae, Alcaligenaceae, and Ruminococcaceae[49]. According to research on animals, the gut microbiota can influence social behaviour, communication, stress, and depression[50]. Furthermore, faecal microbiota transplantation can transfer behavioural features between mice strains[14]. Furthermore, new research indicates that behavioural characteristic alterations may be influenced by microbiota[51]. In addition, GM has been linked in numerous studies to the advancement of pancreatic cancer[22, 52, 53]. The study conducted by Ren (2017) revealed that the stool microbiome of patients with pancreatic cancer was more diverse and composed of known lipopolysaccharide (LPS)-producing taxa and pathogens, such as *Enterobacter*, *Veillonella*, *Hallella*, *Selenomonas*, *Prevotella*, and *Klebsiella* species, than the microbiome of healthy controls[53].

## RESISTOME


A collection of environmental antibiotic resistance genes, or ARGs, is an antibiotic resistome[54]. According to Moore et al. (2013), the resistome is formed after birth or the first few months of life[55]. According to Yi et al. (2022), the microbiota serves as a reservoir for resistomes or ARGs[56]. According to Stecher and Hardt (2011), colonisation resistance is a method the gut microbiota uses to resist different infections[57]. Numerous factors can impact ARGs, such as the use of live microbial therapies, antibiotics, the severity of the illness, the hospital setting, nursing, agriculture, location, and nutrition (Figure 1) [58]. In addition, metagenomics based on next-generation sequencing technologies, the human microbiomes, and their resistome found in the skin, respiratory tract, and gut have been evaluated. Understanding the dynamics of the human resistome and how it relates to the health sectors is crucial for controlling ARG that flows from the other sectors to the human sector, especially ARG transfer to bacteria that cause disease[59]. The human microbiome's commensal bacteria serve as clinical ARGs' primary reservoir and transmission route[60]. Several research studies have uncovered its function by interpreting the gut resistome and contrasting its similarities with pathogens[61-63]. A suggested indirect effect has drawn more attention to resistome: commensal species may share their resistome with pathobionts or pathogens, potentially passing it on to clinically and virulently relevant strains[64]. Commensal bacteria may be the source of the resistome that supported the discovery of the *vanB* genes in the vancomycin-resistant gut that was separated from *Eggerthella* and *Clostridium innocuum*[65].



**Fig. 1. The description of the factors that affect the resistome. Taken after Crits-Christoph et al. (2022)[58].**

### **ANTIBIOTIC RESISTANCE GENES (ARGS)**

A collection of antibiotic resistance genes (ARGs) in a microbial community or on a single bacterium is referred to as a resistome. Resistome has been studied in a variety of settings, including the human gut, soils, animals, and oceans (Figure 2)[66]. Furthermore, metagenomic whole-genome shotgun sequencing (mWGS) will make additional ARGs available as newly sequenced bacterial genomes become available[67]. ARGs are categorised as intrinsic (originating from the producers) or acquired (from other bacteria) resistant (Figure 3)[68].



**Fig. 2. Description of the reservoir of ARGs. Taken after Cuadrat et al. (2020) [66].**




Antibiotic resistance genes (ARGs) can be classified into

Acquired (from other bacteria)

Intrinsic (from the producers)

**Fig. 3. The classification of ARGs. Taken after Hu et al. (2017) [68].**

ARGs, which shield the cell from antibiotics, can develop from susceptible bacteria by accumulating mutations or obtaining resistance genes through transformation, transduction, and conjugation[15]. Moreover, global cell adaptations, ribosomal protection protein, antibiotic target replacement, inactivation, and antibiotic modifications (Figure 4) are the primary mechanisms of antibiotic resistance. These mechanisms include changing the antibiotic target by lowering the affinity of the binding site for the antibiotic. Drug efflux, drug target modification, and drug inactivation were the methods of acquired resistance; drug efflux, limiting uptake, and drug inactivation might be intrinsic resistance mechanisms[69]. As previously indicated, these mechanisms may be innate to the microorganisms or acquired from other microbes[69].



**Fig. 4. Types of antimicrobial resistance mechanisms in bacteria. Taken after Munita and Arias (2016)[16].**

The five primary categories of antimicrobial processes are depolarising the cell membrane, blocking bacterial pathways, blocking the creation of proteins and nucleic acids, and inhibiting cell walls. Table 1 displays examples of how antimicrobial group-based mechanisms work. Moreover, resistance levels within the bacterial groupings may vary dramatically. Minimum inhibitory concentration (MIC) is used to quantify susceptibility and resistance. The range of MICs for any antibiotic among different bacterial species is known as drug susceptibility. The species is thought to have intrinsic resistance to the medication even if it is in the resistant portion of the MIC range. The genes that bacteria acquire and the species they belong to determine their resistance levels[69].

Table 1. The actions of ARGs are based on the antimicrobial groups. Taken after[69].

<b>Action of ARGs</b>	<b>Antimicrobial drug groups</b>
<b>Inhibit cell wall synthesis.</b>	B-Lactams, Cephalosporins, Penicillins
<b>Inhibit protein synthesis.</b>	Aminoglycosides, Tetracyclines, Macrolides
<b>Inhibit nucleic acid synthesis.</b>	Fluoroquinolones

Natural resistance can be produced by intrinsic genes always expressed in the species or by naturally occurring genes in bacteria that are expressed only to the resistant levels following antibiotic exposure. The feature that all bacteria have in common is intrinsic resistance, which has nothing to do with horizontal gene transfer or prior exposure to antibiotics (Table 2). For instance, the structure and function of the lipopolysaccharide (LPS) layer in gram-negative bacteria acts as a barrier to a wide range of molecules, giving the bacteria an inherent resistance to various antimicrobial drugs. For example, because *Mycobacteria* has a lipid outer membrane, hydrophobic drugs—like rifampicin and fluoroquinolones—have easy access to the cell, while hydrophilic drugs are more restricted in their absorption[70-72]. Moreover, *Mycoplasma* is inherently resistant to antibiotics that attack the cell wall, such as  $\beta$ -lactams and glycopeptides[73]. Gram-positive bacteria have an outer barrier that keeps drugs from entering the cell. For instance, enterococci's cell wall contains polar compounds that hinder cell wall penetration and confer an inherent resistance to aminoglycosides[70]. Gram-positive *Staphylococcus aureus* bacteria are resistant to vancomycin. Vancomycin-resistant *S. aureus* (VISA) strains have produced a thickened cell wall, which hinders the drug's ability to enter the cell and confers resistance[70, 74].

Table 2. Some bacterial species have intrinsic resistance to antimicrobial drugs. Taken after several reports [70-72].

<b>Organism</b>	<b>Intrinsic resistance</b>
<b><i>Bacteroides (anaerobes)</i></b>	Aminoglycosides, many $\beta$ -lactams, quinolones
<b><i>Enterococci</i></b>	Aminoglycosides, cephalosporins, lincosamides
<b><i>Escherichia coli</i></b>	Macrolides
<b><i>Klebsiella spp.</i></b>	Ampicillin
<b><i>Acinetobacter spp.</i></b>	Ampicillin, glycopeptides

The acquisition of ARGs can be made temporarily or permanently. Plasmid-mediated transmission of resistance genes is the most frequent method of acquiring foreign genetic material; however, bacteriophage transfer is uncommon. However, some bacterial species—like *Acinetobacter spp.*—can obtain genetic material directly from the environment [72]. Additionally, specific genes, such as those that encode antibiotic-modifying enzymes, drug targets, regulators that regulate drug transporters,

and drug transporters, may experience mutations that result in antimicrobial resistance[15].Moreover, the organism determines a great deal of the mutations that contribute to antibiotic resistance. For example, when *S. aureus* develops a methicillin resistance, the bacterial growth rate is dramatically reduced [15]. High resistance levels in subsequent bacterial generations may be selected using very low or low doses of antibacterial drugs (sub-inhibitory)[75].

### **PENICILLIN-BINDING PROTEINS (PBPS)**

The bacterial cells alter the structure and/or quantity of Penicillin-binding proteins (PBPs), which allows the agents to withstand the effects of numerous antimicrobial drugs. Gram-positive bacteria have this process as one of their resistance mechanisms to  $\beta$ -lactam antibiotics. PBPs are transpeptidases that are involved in the cell wall's peptidoglycan production. Therefore, altering the PBP value, either up or down, has an impact on the drug's capacity to bind. PBPs alter the amount of antimicrobial that binds to that target, resulting in structural changes. For instance, PBP2a in *S. aureus* causes resistance by acquiring the *mecA* gene, which can either reduce or prevent the capacity of a medication to bind[15, 69].Furthermore, by depolarising a cell membrane, the glycopeptide vancomycin prevents the formation of cell walls and lipopeptides. Because of the thick LPS coating, gram-negative bacteria are intrinsically resistant to these medications[76, 77].Vancomycin-resistant Enterococci (VRE) and methicillin-resistant *S. aureus* (MRSA) are two types of enterococci where resistance to the antibiotic is a significant problem. On the other hand, resistance is caused by the acquisition of *van* genes, which alters the structure of peptidoglycan precursors and lowers vancomycin's binding capacity[70, 74].Furthermore, a mutation in *mprF* is an important mechanism that inhibits calcium binding by changing the cell membrane's charge to a positive state. As a result, daptomycin cannot bind because of the inhibition of calcium[6, 78].The targeting of ribosomal subunits' antimicrobial resistance can arise through ribosomal methylation or ribosomal mutation (aminoglycosides, oxazolidinones) [78]. Additionally, in bacterial and some eucaryotic organisms, such as *Pneumocystis carinii*[79].*Toxoplasma gondii*), and *Plasmodium falciparum*[79], the enzyme dihydropteroate synthase (DHPS; EC 2.5.1.15) catalyses the biosynthesis of dihydropteroic acid. Synthetic antibacterial agents include sulfonamides (SULs) and trimethoprim (TMP). While TMP treats acute urinary tract infections, the early SUL chemicals were long used to prevent urinary tract infections. Human cells do not possess this enzyme activity. SUL medications function as DHPS competitive inhibitors, preventing the bacterial cell from producing folate, which results in[80].Over the past few years, TMP resistance and significant SUL resistance have seen a noticeable increase. Pathogenic bacteria have exhibited remarkable evolutionary adaptability to the presence of TMP and SUL, as evidenced by their methods of resistance and spread. Despite this, Huovinen et al. (1995) reported alterations in the chromosomal architecture and regulatory processes of the *dhps* and *dhfr* genes, which code for the target enzymes DHPS and DHFR, respectively[81].

## **β-LACTAMASES**

A four-sided β-lactam ring makes up the unique core structure shared by all β-lactam medications. Three main mechanisms were identified for resistance to β-lactam medications: the drug being hydrolysed by β-lactamase enzymes, the drug altering its ability to bind to PBP to prevent interaction, and the existence of efflux pumps that can extrude β-lactam medications[82].). Different types of efflux pumps, known as multi-drug (MDR), can transport more significant quantities of chemicals. Their purpose is to remove harmful molecules from the bacterial cell. Furthermore, many of these pumps' resistance level is affected by the accessible carbon source [83].Cephalosporinases and penicillinases are two types of β-lactamases that block β-lactam medications by hydrolysing a specific location within the β-lactam ring, causing the ring to open. Furthermore, according to Bush and Jacoby (2010), open-ring medications are unable to attach to their intended PBP[84].β-lactamase enzymes are categorised based on features related to their structure and/or molecular functions. They fall under four major structural types. Gram-positive bacteria primarily contain β-lactamases from group A[84, 85].

These enzymes can be inherited from the bacterial chromosome or acquired through a plasmid. Gram-negative bacteria belonging to the Enterobacteriaceae family possess β-lactamase genes on their chromosomes. This enzyme is also present in other Gram-negative bacteria, such as *Acinetobacter* spp., *Pseudomonas* spp., and *Aeromonas* spp. Enterobacteriaceae is a common family that contains β-lactamase genes transmitted by plasmids[86].The ampicillin resistance gene, *ampC*, chromosomally encodes the first β-lactamase described, derived from *E. coli*. The majority of the time, this gene is expressed at a low level; nevertheless, mutations lead to an overexpression of the gene. Penicillins and the first generation of some cephalosporins are affected by β-lactamases encoded by the *AmpC* gene[85, 87-89].

Table 3 displays a summary of the elements of antimicrobial resistance.

Table 3. Examples of antimicrobial resistance elements. Taken after a few reports [85, 87-89].

<b>Drug</b>	<b>Drug uptake limitation</b>	<b>Drug target modification</b>	<b>Drug inactivation</b>	<b>Efflux Pumps</b>
<b>β-Lactams</b>	Decreased numbers of porins, no outer cell wall	Gram-positive alterations in PBPs	Gram-positive, gram-negative β-lactamases	Resistance-nodulation-division (RND)
<b>Cephalosporins</b>	Changed selectivity of porin			
<b>Penicillins</b>	Thickened cell wall, no outer cell wall	Modified peptidoglycan		
<b>Glycopeptides</b>				
<b>Lipopeptides</b>		Modified net cell surface charge		
<b>Aminoglycosides</b>	Cell wall polarity	Ribosomal mutation, methylation	Aminoglycoside modifying enzymes, acetylation, phosphorylation, adenylation	RND
<b>Tetracyclines</b>	Decreased numbers of porins	Ribosomal protection	Antibiotic modification, oxidation	Major facilitator superfamily (MFS), RND
<b>Macrolides</b>		Ribosomal mutation methylation		ATP-binding cassette (ABC) MFS

The human microbiome's commensal bacteria serve as clinical ARGs' primary reservoir and transmission route[60]. Several researchers[61, 62] have unravelled the role of gut resistome and compared its similarity with those of pathogens. Rarely does commensal bacteria transfer ARG to pathogens. Pathogenic bacteria and the human gut have nearly comparable ARGs and genetic settings, indicating GM's significance in forming clinical ARGs[63]. Geographical location, chemotherapeutics (such as antibiotics), and dietary modifications have all been linked to associations between the animal gut and environmental and human gut resistomes[90-92].

## **ASD AND MICROBIOME**

Early-life antibiotic exposure can alter the microbiota composition, which may be a factor in ASD[93].GI problems in ASD are explained by the fact that children with ASD are treated with a greater quantity of antibiotics than healthy children[20].Moreover, oral antibiotics promote the growth of anaerobic bacteria in the gut, including *Desulfovibrio*, *Clostridium*, and phylum Bacteroidetes, which may exacerbate GI symptoms and autistic behaviours in people with ASD[94].Compared to broad-spectrum and moderate-spectrum antibiotics, which increased the effect of ASD, the impact of using narrow-spectrum antibiotics was limited concerning autism[95].). It has been demonstrated that using several antibiotic classes while pregnant may marginally raise the incidence of ASD[20].In the second and third trimesters of pregnancy, penicillin use was documented in 50% of instances of ASD. It has been demonstrated that taking sulfonamides when pregnant increases the likelihood that the child will become infantile [64].Antibiotic use and ASD have not yet been proven to be related [20].

## **CONCLUSION**

The connection between the gut microbiome, antibiotic resistance genes (ARGs), and autism spectrum disorder (ASD) is complex. Environmental factors like early birth, maternal infection during pregnancy, and antibiotic exposure are implicated in the onset and severity of ASD symptoms. The gut microbiome, which comprises diverse bacterial species and genetic reservoirs, is crucial for modulating immune responses influencing brain function and overall health.

Studies have shown that individuals with ASD have changes in their gut microbiota composition and an increased prevalence of antibiotic-resistant genes (ARGs). This finding suggests a potential link between gut dysbiosis, antibiotic exposure, and the manifestation of ASD symptoms. Furthermore, commensal bacteria in the gut can acquire and transmit ARGs, indicating the interconnection between environmental factors and human health. Therefore, Understanding the mechanisms underlying antibiotic resistance and its impact on the gut microbiome is crucial to developing targeted interventions and therapeutic strategies for individuals with ASD. Future research should focus on understanding the complex interplay between environmental exposures, microbial dynamics, and neurodevelopmental outcomes in ASD. By untangling these intricate relationships, we can develop personalised approaches to ASD management, improving the quality of life for affected individuals.

## REFERENCES

1. De Angelis, M., et al., *Autism spectrum disorders and intestinal microbiota*. Gut microbes, 2015. **6**(3): p. 207-213.
2. Agrawal, S., et al., *Prevalence of autism spectrum disorder in preterm infants: a meta-analysis*. Pediatrics, 2018. **142**(3).
3. Christensen, J., et al., *Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism*. Jama, 2013. **309**(16): p. 1696-1703.
4. Atladóttir, H.Ó., et al., *Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders*. Journal of autism and developmental disorders, 2010. **40**(12): p. 1423-1430.
5. (CDC), C.f.d.c.a.p. *Autism spectrum disorders*. 2018; Available from: <https://www.cdc.gov/>
6. Yang, X., N. Zhang, and P. Schrader, *A study of brain networks for autism spectrum disorder classification using resting-state functional connectivity*. Machine Learning with Applications, 2022. **8**: p. 100290.
7. Hughes, H.K., D. Rose, and P. Ashwood, *The gut microbiota and dysbiosis in autism spectrum disorders*. Current neurology and neuroscience reports, 2018. **18**: p. 1-15.
8. Özcan, E. and E.Y. Hsiao, *Are changes in the gut microbiome a contributor or consequence of autism—why not both?* Cell Reports Medicine, 2022. **3**(1): p. 100505.
9. MacFabe, D.F., *Enteric short-chain fatty acids: microbial messengers of metabolism, mitochondria, and mind: implications in autism spectrum disorders*. Microbial ecology in health and disease, 2015. **26**(1): p. 28177.
10. Fjalstad, J.W., et al., *Antibiotic therapy in neonates and impact on gut microbiota and antibiotic resistance development: a systematic review*. Journal of Antimicrobial Chemotherapy, 2018. **73**(3): p. 569-580.
11. Gibson, M.K., et al., *Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome*. Nature microbiology, 2016. **1**(4): p. 1-10.
12. Krajmalnik-Brown, R., et al., *Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease*. Microbial Ecology in Health and Disease, 2015. **26**(1): p. 26914.
13. Schulfer, A.F., et al., *Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice*. Nature microbiology, 2018. **3**(2): p. 234-242.
14. Collins, S.M., Z. Kassam, and P. Bercik, *The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications*. Current opinion in microbiology, 2013. **16**(3): p. 240-245.
15. Martinez, J.L., *General principles of antibiotic resistance in bacteria*. Drug Discovery Today: Technologies, 2014. **11**: p. 33-39.
16. Munita, J.M. and C.A. Arias, *Mechanisms of antibiotic resistance*. Virulence mechanisms of bacterial pathogens, 2016: p. 481-511.
17. Zhang, X.-X., T. Zhang, and H.H. Fang, *Antibiotic resistance genes in water environment*. Applied microbiology and biotechnology, 2009. **82**: p. 397-414.
18. Liu, B. and M. Pop, *ARDB—antibiotic resistance genes database*. Nucleic acids research, 2009. **37**(suppl\_1): p. D443-D447.

19. Bittker, S.S. and K.R. Bell, *Acetaminophen, antibiotics, ear infection, breastfeeding, vitamin D drops, and autism: an epidemiological study*. *Neuropsychiatric disease and treatment*, 2018. **14**: p. 1399.
20. Kovtun, A.S., et al., *Antibiotic resistance genes in the gut microbiota of children with autistic spectrum disorder as possible predictors of the disease*. *Microbial Drug Resistance*, 2020. **26**(11): p. 1307-1320.
21. Sharma, V.K., et al., *A review of the influence of treatment strategies on antibiotic resistant bacteria and antibiotic resistance genes*. *Chemosphere*, 2016. **150**: p. 702-714.
22. Pulikkan, J., A. Mazumder, and T. Grace, *Role of the gut microbiome in autism spectrum disorders*. *Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders*, 2019: p. 253-269.
23. Lord, C., et al., *Autism spectrum disorder*. *The lancet*, 2018. **392**(10146): p. 508-520.
24. Forsyth, A., et al., *Autism Spectrum Disorder in Children: Behavioral, Sensory and Gastrointestinal Considerations and Assessment of Oral Health*. *J Dent Oral Biol*. 2018; 3 (4), 2018. **1138**.
25. Floris, D.L., et al., *Atypical brain asymmetry in autism—a candidate for clinically meaningful stratification*. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 2021. **6**(8): p. 802-812.
26. Hemmati, M., et al., *Importance of heme oxygenase-1 in gastrointestinal cancers: functions, inductions, regulations, and signaling*. *Journal of Gastrointestinal Cancer*, 2021. **52**(2): p. 454-461.
27. Sabbagh, H.J., et al., *Prevalence and characteristics of autistic children attending autism centres in 2 major cities in Saudi Arabia: A cross-sectional study*. *Saudi medical journal*, 2021. **42**(4): p. 419.
28. Khan, A.S., et al., *Autism in Saudi Arabia, a challenge to Saudi families: a cross-sectional study*. *International Journal of Medicine in Developing Countries*, 2020. **4**(9): p. 1453-1458.
29. Hayat, A.A., et al., *Assessment of knowledge about childhood autism spectrum disorder among healthcare workers in Makkah-Saudi Arabia*. *Pakistan journal of medical sciences*, 2019. **35**(4): p. 951.
30. Pourmohamadreza-Tajrishi, M. and P. Azadfallah, *The Effectiveness of Therapeutic Exercise on Motor Skills and Attention of Male Students with Autism Spectrum Disorder*. *International Journal of Psychological and Behavioral Sciences*, 2019. **13**(7): p. 354-358.
31. Zeidan, J., et al., *Global prevalence of autism: a systematic review update*. *Autism Research*, 2022. **15**(5): p. 778-790.
32. First, M.B., *Paradigm shifts and the development of the diagnostic and statistical manual of mental disorders: past experiences and future aspirations*. *The Canadian Journal of Psychiatry*, 2010. **55**(11): p. 692-700.
33. Jassim, N., S. Baron-Cohen, and J. Suckling, *Meta-analytic evidence of differential prefrontal and early sensory cortex activity during non-social sensory perception in autism*. *Neuroscience & Biobehavioral Reviews*, 2021. **127**: p. 146-157.
34. Rossignol, D.A., S.J. Genuis, and R.E. Frye, *Environmental toxicants and autism spectrum disorders: a systematic review*. *Translational psychiatry*, 2014. **4**(2): p. e360-e360.
35. Almandil, N.B., et al., *Environmental and genetic factors in autism spectrum disorders: Special emphasis on data from Arabian studies*. *International journal of environmental research and public health*, 2019. **16**(4): p. 658.
36. Hewitt, A., et al., *Autism spectrum disorder (ASD) prevalence in Somali and non-Somali children*. *Journal of Autism and Developmental Disorders*, 2016. **46**(8): p. 2599-2608.

37. Mead, J. and P. Ashwood, *Evidence supporting an altered immune response in ASD*. Immunology letters, 2015. **163**(1): p. 49-55.
38. Marchesi, J.R. and J. Ravel, *The vocabulary of microbiome research: a proposal*. 2015, Springer. p. 1-3.
39. Schmidt, T.S., J. Raes, and P. Bork, *The human gut microbiome: from association to modulation*. Cell, 2018. **172**(6): p. 1198-1215.
40. Belkaid, Y. and T.W. Hand, *Role of the microbiota in immunity and inflammation*. Cell, 2014. **157**(1): p. 121-141.
41. Zhang, X.-S., et al., *Antibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunity*. Elife, 2018. **7**.
42. Guerreiro, C.S., et al., *Diet, microbiota, and gut permeability—the unknown triad in rheumatoid arthritis*. Frontiers in Medicine, 2018. **5**: p. 349.
43. Scher, J.U., et al., *Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis*. elife, 2013. **2**: p. e01202.
44. Wells, P.M., et al., *Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study*. The Lancet Rheumatology, 2020. **2**(7): p. e418-e427.
45. Alpizar-Rodriguez, D., et al., *Prevotella copri in individuals at risk for rheumatoid arthritis*. Annals of the rheumatic diseases, 2019. **78**(5): p. 590-593.
46. Ghoshal, U.C., et al., *The gut microbiota and irritable bowel syndrome: friend or foe?* International journal of inflammation, 2012. **2012**.
47. Chen, J., et al., *An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis*. Genome medicine, 2016. **8**(1): p. 1-14.
48. Rogers, G., et al., *From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways*. Molecular psychiatry, 2016. **21**(6): p. 738-748.
49. Hsiao, E.Y., et al., *Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders*. Cell, 2013. **155**(7): p. 1451-1463.
50. Bruce-Keller, A.J., J.M. Salbaum, and H.-R. Berthoud, *Harnessing gut microbes for mental health: getting from here to there*. Biological psychiatry, 2018. **83**(3): p. 214-223.
51. Kurokawa, S., et al., *The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: an open-label observational study*. Journal of affective disorders, 2018. **235**: p. 506-512.
52. Half, E., et al., *Fecal microbiome signatures of pancreatic cancer patients*. Scientific reports, 2019. **9**(1): p. 1-12.
53. Ren, Z., *Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China*. Oncotarget. **8**, 95176–95191. 2017.
54. D'Costa, V.M., et al., *Sampling the antibiotic resistome*. Science, 2006. **311**(5759): p. 374-377.
55. Moore, A.M., et al., *Pediatric fecal microbiota harbor diverse and novel antibiotic resistance genes*. PloS one, 2013. **8**(11): p. e78822.
56. Yi, X., et al., *Inflammatory Endotype-Associated Airway Resistome in Chronic Obstructive Pulmonary Disease*. Microbiology Spectrum, 2022. **10**(2): p. e02593-21.
57. Stecher, B. and W.-D. Hardt, *Mechanisms controlling pathogen colonization of the gut*. Current opinion in microbiology, 2011. **14**(1): p. 82-91.
58. Crits-Christoph, A., et al., *Good microbes, bad genes? The dissemination of antimicrobial resistance in the human microbiome*. Gut Microbes, 2022. **14**(1): p. 2055944.
59. Wright, G.D., *Environmental and clinical antibiotic resistomes, same only different*. Current opinion in microbiology, 2019. **51**: p. 57-63.

60. Surette, M.D. and G.D. Wright, *Lessons from the environmental antibiotic resistome*. Annual Review of Microbiology, 2017. **71**: p. 309-329.
61. Forsberg, K.J., et al., *The shared antibiotic resistome of soil bacteria and human pathogens*. science, 2012. **337**(6098): p. 1107-1111.
62. Raymond, F., et al., *Culture-enriched human gut microbiomes reveal core and accessory resistance genes*. Microbiome, 2019. **7**(1): p. 1-13.
63. Sommer, M.O., G. Dantas, and G.M. Church, *Functional characterization of the antibiotic resistance reservoir in the human microflora*. science, 2009. **325**(5944): p. 1128-1131.
64. Murray, C.J., et al., *Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis*. The Lancet, 2022. **399**(10325): p. 629-655.
65. Stinear, T.P., et al., *Enterococcal vanB resistance locus in anaerobic bacteria in human faeces*. The lancet, 2001. **357**(9259): p. 855-856.
66. Cuadrat, R.R., et al., *Global ocean resistome revealed: Exploring antibiotic resistance gene abundance and distribution in TARA Oceans samples*. GigaScience, 2020. **9**(5): p. g1aa046.
67. Xavier, B.B., et al., *Consolidating and exploring antibiotic resistance gene data resources*. Journal of clinical microbiology, 2016. **54**(4): p. 851-859.
68. Hu, Y., G.F. Gao, and B. Zhu, *The antibiotic resistome: gene flow in environments, animals and human beings*. Frontiers of Medicine, 2017. **11**(2): p. 161-168.
69. Reygaert, W.C., *An overview of the antimicrobial resistance mechanisms of bacteria*. AIMS microbiology, 2018. **4**(3): p. 482.
70. Cox, G. and G.D. Wright, *Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions*. International Journal of Medical Microbiology, 2013. **303**(6-7): p. 287-292.
71. Fajardo, A., et al., *The neglected intrinsic resistome of bacterial pathogens*. PloS one, 2008. **3**(2): p. e1619.
72. Kumar, A. and H.P. Schweizer, *Bacterial resistance to antibiotics: active efflux and reduced uptake*. Advanced drug delivery reviews, 2005. **57**(10): p. 1486-1513.
73. Bébéar, C. and S. Pereyre, *Mechanisms of drug resistance in Mycoplasma pneumoniae*. Current Drug Targets-Infectious Disorders, 2005. **5**(3): p. 263-271.
74. Beceiro, A., M. Tomás, and G. Bou, *Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?* Clinical microbiology reviews, 2013. **26**(2): p. 185-230.
75. Blázquez, J., et al., *Antimicrobials as promoters of genetic variation*. Current opinion in microbiology, 2012. **15**(5): p. 561-569.
76. Randall, C.P., et al., *The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens*. Antimicrobial agents and chemotherapy, 2013. **57**(1): p. 637-639.
77. Wood, T.K., S.J. Knabel, and B.W. Kwan, *Bacterial persister cell formation and dormancy*. Applied and environmental microbiology, 2013. **79**(23): p. 7116-7121.
78. Stefani, S., et al., *Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence*. International journal of antimicrobial agents, 2015. **46**(3): p. 278-289.
79. VOLPE, F., S.P. BALLANTINE, and C.J. DELVES, *The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase*. European journal of biochemistry, 1993. **216**(2): p. 449-458.
80. GM, B., *The biosynthesis of folic acid. II. Inhibition by sulfonamides*. The Journal of Biological Chemistry, 1962. **237**: p. 536-540.
81. Huovinen, P., et al., *Trimethoprim and sulfonamide resistance*. Antimicrobial agents and chemotherapy, 1995. **39**(2): p. 279-289.

82. Bush, K. and P.A. Bradford,  *$\beta$ -Lactams and  $\beta$ -lactamase inhibitors: an overview*. Cold Spring Harbor perspectives in medicine, 2016. **6**(8).
83. Blair, J.M., G.E. Richmond, and L.J. Piddock, *Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance*. Future microbiology, 2014. **9**(10): p. 1165-1177.
84. Bush, K. and G.A. Jacoby, *Updated functional classification of  $\beta$ -lactamases*. Antimicrobial agents and chemotherapy, 2010. **54**(3): p. 969-976.
85. Schultsz, C. and S. Geerlings, *Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy*. Drugs, 2012. **72**: p. 1-16.
86. Chancey, S.T., D. Zähler, and D.S. Stephens, *Acquired inducible antimicrobial resistance in Gram-positive bacteria*. Future microbiology, 2012. **7**(8): p. 959-978.
87. Bevan, E.R., A.M. Jones, and P.M. Hawkey, *Global epidemiology of CTX-M  $\beta$ -lactamases: temporal and geographical shifts in genotype*. Journal of antimicrobial chemotherapy, 2017. **72**(8): p. 2145-2155.
88. Bush, K., *Proliferation and significance of clinically relevant  $\beta$ -lactamases*. Annals of the New York Academy of Sciences, 2013. **1277**(1): p. 84-90.
89. Pfeifer, Y., A. Cullik, and W. Witte, *Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens*. International journal of medical microbiology, 2010. **300**(6): p. 371-379.
90. Pehrsson, E.C., et al., *Interconnected microbiomes and resistomes in low-income human habitats*. Nature, 2016. **533**(7602): p. 212-216.
91. Sun, J., et al., *Environmental remodeling of human gut microbiota and antibiotic resistome in livestock farms*. Nature communications, 2020. **11**(1): p. 1-11.
92. Van Gompel, L., et al., *Description and determinants of the faecal resistome and microbiome of farmers and slaughterhouse workers: a metagenome-wide cross-sectional study*. Environment international, 2020. **143**: p. 105939.
93. Whelan, J., *Antibiotics: a possible treatment for regressive-onset autism*. Drug Discovery Today, 2000. **5**(11): p. 487-488.
94. Bolte, E., *Autism and Clostridium tetani*. Medical hypotheses, 1998. **51**(2): p. 133-144.
95. Wimberley, T., et al., *Otitis media, antibiotics, and risk of autism spectrum disorder*. Autism Research, 2018. **11**(10): p. 1432-1440.